Future studies characterising the CIR‐induced phenotype would benefit from (1) body mass recovery–directed endpoints, (2) investigation of multiple CIR cycle impacts as is often used clinically and (3) daily muscle and blood sampling across the AML CIR to tease out the contributions of each of daunorubicin and cytarabine to muscle and plasma proteome changes and determine whether Hp has advantages over traditional serum cachexia biomarkers (e.g., Crp and inflammatory cytokines). Here, HP is linked to acute myeloid leukemia.